BioSpace News Archive

BioInvent International AB announces that its anti-FcyRllB antibody BI-1206 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of follicular lymphoma, the most common form of slow-growing Non-Hodgkin lymphoma.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced the presentation of the study design for its phase III trial, COMPOSE, at the ASCO Gastrointestinal Cancers Symposium, held from January 20 – 22, 2022.

Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces the detailed results of the dose escalation phase of its clinical phase 1/2 study conducted with ABX196 for the treatment of hepatocellular carcinoma, to be presented at the ASCO GI Cancers Symposium on January 20-22, 2022.

Novotech Health Holdings Pte. Ltd. announced the completion of a financing round of US$760 million comprising a US$255 million private placement and a US$505 million refinancing transaction, setting itself as the leading Asia-Pacific biotech specialist Contract Research Organization to pursue further growth opportunities by M&A in geographical expansion as well as data, AI and tech-enabled offerings.

Sai Life Sciences, a leading global Contract Research, Development & Manufacturing Organization, announced the appointment of Sauri Gudlavalleti as its Chief Operating Officer.